Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 3
Submit an article Journal homepage
108
Views
4
CrossRef citations to date
0
Altmetric
Letter

Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors

Xiangdong XuDepartment of Pathology and Immunology, Washington University, School of Medicine, St. Louis, MO, USA;Department of Pathology, VA San Diego Healthcare System, San Diego, CA, USACorrespondence[email protected]
&
Anjum HassanDepartment of Pathology and Immunology, Washington University, School of Medicine, St. Louis, MO, USA
Pages 715-717 | Received 09 Apr 2013, Accepted 31 May 2013, Published online: 20 Aug 2013

References

  • Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119: 1981–1987.
  • Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 2012;10:14–24.
  • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
  • Roy L, Guilhot J, Martineau G, et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005;19:1689–1692.
  • Pilot PR, Sablinska K, Owen S, et al. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006;20:148; author reply 149.
  • Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353–4358.
  • Duman BB, Paydas S, Disel U, et al. Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma 2012;53:1706–1708.
  • Garipidou V, Vakalopoulou S, Tziomalos K. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate. Oncologist 2005;10:457–458.
  • Bhagavathi S, Borromeo V, Desai H, et al. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. Ann Clin Lab Sci 2008;38:405–409.
  • Galanopoulos A, Papadhimitriou SI, Kritikou-Griva E, etal. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia. Ann Hematol 2009;88:281–282.
  • Ide M, Kuwahara N, Matsuishi E, et al. Uncommon case of chronic myeloid leukemia with multiple myeloma. Int J Hematol 2010;91: 699–704.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.